United States : MappBios wins deal with BARDA for ZMapp and additional filovirus medical.
Mapp Biopharmaceutical, Inc., has announced today that it has secured a Project BioShield contract (HHSO100201700017C) worth around $46 million from The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance ZMappTM to licensure by the Food and Drug Administration (FDA).
A separate deal (HHSO100201700023C) worth $1.9 million has been awarded (with options for a further $6.6 million) to support Mapps preclinical stage products for Sudan virus (MBP134) and pan-Marburg virus (MBP091).
ZMapp is a monoclonal antibody cocktail to treat Ebola Virus Disease (EVD) that has yielded promising safety and efficiency information from animal models and the PREVAIL II clinical test conducted during the 2013-2016 outbreak in West Africa. ZMapp is currently being made available to EVD patients through an Expanded Access Protocol offered to sites in the United States, Guinea, Liberia, and Sierra Leone.
The Project BioShield contract involves a 5-year commitment, with options for a further funding of $297 million that could extend the agreement an additional five years, and separate options for procurement of ZMapp for the Strategic National Stockpile.
Dr. Kenneth G. Payie, Chief Operating Officer and Principal Investigator on the ZMapp contract, said, We are pleased to continue our productive relationship with BARDA, and believe both these programs represent strong examples of public-private partnership to advance much needed therapeutics for patients and the Strategic National Stockpile.
[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 3, 2017|
|Previous Article:||Egypt : Govt. may soon sign Dabaa nuclear power plant deal.|
|Next Article:||Japan : ivWatch signs distribution deal with Japanese medical device company.|